Article

The immunomodulatory properties of the HDAC6 inhibitor ACY241 supports robust anti-tumor response in NSCLC when coupled with the chemotherapy drug Oxaliplatin

2021-10-02

Abstract excerpt

<h4>Background</h4> Durable treatments that benefit a wide pool of patients remain elusive for Non-small cell lung cancer (NSCLC). The success of immunotherapy in a subset of NSCLC patients highlights the potential contribution of immune response to anti-tumor immunity while underscoring a need for broadly applicable therapeutic strategies. HDAC inhibitors are a promising class of drugs whose immunomodulatory pro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 71300049-d6b0-5e20-9f0b-efedd496b4b8
DOI: 10.1101/2021.10.01.462824

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The immunomodulatory properties of the HDAC6 inhibitor ACY241 supports robust anti-tumor response in NSCLC when coupled with the chemotherapy drug OxaliplatinDOI 10.1101/2021.10.01.462824Read

HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-Driven Small Cell Lung CancerSemantic proximity Read

TNF⍰-mediated myeloid-instructed CD14 <sup>+</sup> CD4 <sup>+</sup> T cells within the tumor microenvironment are associated with poor survival in non-small cell lung cancerSemantic proximity Read

Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulationSemantic proximity Read

IRF4 instructs effector Treg differentiation and immune suppression in human cancerSemantic proximity Read

A pan‐cancer analysis identifies HDAC11 as an immunological and prognostic biomarkerSemantic proximity Read

Immune modulation underpins the anti‐cancer activity of HDAC inhibitorsSemantic proximity Read

HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseasesSemantic proximity Read

Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: New chances for sophisticated drug design and treatment optimizationSemantic proximity Read

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung CancerSemantic proximity Read

The Presence of CD11c+ B Cells with Potent Effector Memory Phenotype in Lung Adenocarcinoma Correlates with Overall Patient Survival.Semantic proximity Read

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.Semantic proximity Read

A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with ImmunotherapySemantic proximity Read